Vivani Medical 株価情報 (NASDAQ: VANI)

最新ニュース Vivani Medical (NASDAQ:VANI) 株価情報

Vivani Medical

Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.

Vivani Medical Inc

Vivani Medical Inc Warrants (14/03/2024)

Vanilla Network

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 10 years by 11.19% on an annualized basis producing an average annual return of 22.11%. Currently, Meta Platforms has a market capitalization of $1.51 trillion. 
Buying $1000 In META: If an investor had bought $1000 of META stock 10 years ago, it would be worth $7,388.29 today based on a price of $597.04 for META at the time of writing.
<h3>Meta Platforms's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734651910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Meta Platforms 10 Years Ago Would Be Worth This Much Today

The debate over how to tackle America's obesity epidemic that affects 40% of adults and nearly<a href="https://www.benzinga.com/general/biotech/24/02/37157967/whats-gaining-popularity-among-us-teens-battling-obesity-novo-nordisks-weight-loss-drug-wegovy" target="_blank" rel="noreferrer noopener">&nbsp;20% of children</a>, has sparked contrasting views from two influential voices in President-elect Donald J. Trump's orbit. The side that wins could have a lasting impact on public health in the U.S.
Robert F. Kennedy Jr., <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">Trump's pick</a> for secretary of Health and Human Services (HHS), says lifestyle changes need to be a big part of the solution.
Elon Musk, billionaire tech entrepreneur and seemingly one of Trump's closest advisers, is calling for easier access to weight loss drugs such as <a href="https://www.benzinga.com/topic/ozempic">Ozempic</a> and <a href="https://www.benzinga.com/topic/wegovy">Wegovy</a>, produced by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>). Musk, who has used Wegovy, said on X that &#8220;nothing else is even close&#8221; when considering how to address obesity, <a href="https://www.nytimes.com/2024/12/18/health/ozempic-food-rfk-elon-musk.html">noted</a> the New York Times. "Nothing would do more to improve the health, lifespan, and quality of life for Americans than making GLP inhibitors super low cost to the public."
Kennedy, meanwhile, says if approved to lead the HHS, he'll roll out an anti-obesity plan that will focus on healthier nutrition and encouraging Americans to make time for daily exercise. Kennedy told Fox News' Greg Gutfeld before the election that the makers of obesity drugs are &#8220;counting on selling it to Americans because we're so stupid and so addicted to drugs.&#8221;
<h1 class="wp-block-heading">Suicide and Ozempic?</h1>
Kennedy <a href="https://www.youtube.com/watch?v=qX9nQ40mSMY">said in the same Fox News appearance</a> that the European Union "is right now investigating Ozempic for suicidal ideation," although the EU regulator concluded in April that available evidence does not suggest Ozempic and other weight-loss drugs cause suicidal thoughts or actions.
Dr. Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota says such confident although false or misleading assertions are Kennedy's trademark. And they can be dangerous, Osterholm warned, when applied to public health bedrocks like vaccines.
"He acts like he knows what he's talking about when he doesn't, and he says things with a definition that makes people convinced he has the data to support his statement," Osterholm <a href="https://www.cnn.com/2024/11/17/health/rfk-jr-ozempic/index.html">told</a> CNN two weeks after the November election. "Trying to follow him and understand what he's talking about is often like trying to nail Jell-O to the wall."
Kennedy and Musk's competing perspectives underscore the difficult path toward dealing with the U.S.'s <a href="https://www.benzinga.com/news/24/03/37413349/ozempic-wegovy-other-weight-loss-drugs-wont-solve-global-obesity-crisis-affecting-1b-people-who-warn" target="_blank" rel="noreferrer noopener">severe obesity epidemic</a>: lifestyle changes vs. pharmaceuticals.
<h1 class="wp-block-heading">Cannabis a Solution?</h1>
Some people may look to <a href="https://www.benzinga.com/cannabis">cannabis</a> for a natural solution. Recent studies have <a href="https://www.nature.com/articles/s41366-023-01399-x" target="_blank" rel="noreferrer noopener">suggested</a> &#8220;cannabis and subproducts could be considered adjuncts in obesity treatment by helping to reduce relevant anthropometric measurements.&#8221;
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42491683/rfk-jrs-lawyer-urges-fda-to-revoke-polio-vaccine-approval-endangering-millions-of-children">Kennedy&#8217;s Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children</a></li>
</ul>

Cannabis

Government

Health Care

Politics

Elon Musk Vs. RFK Jr.: Obesity Crisis Debate Sparks Struggle For Trump's Influence

Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) has outperformed the market over the past 20 years by 1.81% on an annualized basis producing an average annual return of 10.01%. Currently, Nike has a market capitalization of $115.16 billion. 
Buying $1000 In NKE: If an investor had bought $1000 of NKE stock 20 years ago, it would be worth $6,789.21 today based on a price of $77.37 for NKE at the time of writing.
<h3>Nike's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734651013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Nike 20 Years Ago Would Be Worth This Much Today

Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) has outperformed the market over the past 15 years by 14.86% on an annualized basis producing an average annual return of 26.48%. Currently, Chipotle Mexican Grill has a market capitalization of $84.14 billion. 
Buying $1000 In CMG: If an investor had bought $1000 of CMG stock 15 years ago, it would be worth $34,170.91 today based on a price of $61.75 for CMG at the time of writing.
<h3>Chipotle Mexican Grill's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734650109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chipotle Mexican Grill Stock In The Last 15 Years

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 4.07% on an annualized basis producing an average annual return of 15.69%. Currently, Verisk Analytics has a market capitalization of $38.91 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $894.74 today based on a price of $275.58 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734649208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) has outperformed the market over the past 20 years by 1.69% on an annualized basis producing an average annual return of 9.89%. Currently, Jones Lang LaSalle has a market capitalization of $11.72 billion. 
Buying $1000 In JLL: If an investor had bought $1000 of JLL stock 20 years ago, it would be worth $6,666.58 today based on a price of $246.93 for JLL at the time of writing.
<h3>Jones Lang LaSalle's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734648313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Jones Lang LaSalle 20 Years Ago Would Be Worth This Much Today

BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/24/12/ac42605872/blackberry-reports-third-quarter-fiscal-year-2025-results">from the quarter</a>.
Q3 Earnings: BlackBerry reported third-quarter revenue of $162 million. The company reported third-quarter adjusted earnings of two cents per share, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> for a loss of one cent per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
IoT revenue was&nbsp;$62&nbsp;million, up 13% year-over-year.&nbsp;Cybersecurity revenue totaled $93&nbsp;million in the quarter, up 7% year-over-year. Licensing revenue&nbsp;came in at $7&nbsp;million.
Total company gross margin was 74% in the quarter. Operating cash flow improved by $34 million year-over-year to $3 million. BlackBerry ended the quarter with $266 million in&nbsp;cash, cash equivalents and&nbsp;short-&nbsp;and long-term investments.
&#8220;BlackBerry achieved a significant inflection in its results this past quarter. Driven by a combination of strong revenue performance for both our Cybersecurity and IoT divisions, and continued focus on costs and efficiency, the company delivered stronger than expected profitability and a return to positive cash flow ahead of schedule,&#8221; said John Giamatteo, CEO of BlackBerry. 
From Last Week: <a href="https://www.benzinga.com/24/12/42477300/russian-state-backed-hackers-target-ukrainian-military-devices-via-spacexs-starlink-microsoft-report-reveals">Russian State-Backed Hackers Target Ukrainian Military Devices Via SpaceX&#8217;s Starlink, Microsoft Reveals</a>
Guidance: BlackBerry expects fourth-quarter revenue of $126 million to $135 million versus estimates of $161.49 million. The company anticipates fourth-quarter IoT revenue of $60 million to $65 million, secure communications revenue of $62 million to $66 million and licensing and other revenue of approximately $4 million.
BlackBerry expects full-year revenue of $517 million to $526 million versus estimates of $603.12 million. The company anticipates full-year adjusted earnings to be somewhere between breakeven and a loss of two cents per share, versus estimates for a loss of two cents per share.
Management will further discuss the quarter on a call with investors and analysts at 5:30 p.m. ET.
BB Price Action:&nbsp;<a href="https://www.benzinga.com/quote/BB" target="_blank" rel="noreferrer noopener">BlackBerry shares</a>&nbsp;were up 0.17% in after hours, trading at $2.98 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of BlackBerry.

Earnings

Movers

Tech

BlackBerry Beats Q3 Earnings Estimates, But Soft Guidance Keeps Shares In Check

Legal

SVCO

Silvaco Says US Court Of Appeals For The Ninth Circuit Affirmed US District Court's Dismissal Of All Claims Brought By Aldini

ALLETE Says FERC Approved Proposed Transaction With CPP Investments And Global Infrastructure Partners

Guidance

PARR

Par Pacific Expects 2025 Capital Expenditure And Turnaround Outlay Guidance Of $210M - $240M

Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 10 years by 2.76% on an annualized basis producing an average annual return of 13.69%. Currently, Marsh &amp; McLennan has a market capitalization of $103.31 billion. 
Buying $100 In MMC: If an investor had bought $100 of MMC stock 10 years ago, it would be worth $360.25 today based on a price of $210.35 for MMC at the time of writing.
<h3>Marsh &amp; McLennan's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734647416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Marsh & McLennan 10 Years Ago Would Be Worth Today

SPRY

ARS Pharmaceuticals Says Express Scripts Has Added neffy (Epinephrine Nasal Spray) To Its Commercial National Formularies

The Stock Repurchase Program will begin on December 19, 2024 and conclude on December 19, 2025.

Buybacks

FRST

Primis Financial Board Approves Stock Repurchase Program For Up To 740,600 Of Outstanding Shares Of Common Stock

As a result of this error, the Bank will record $8.1 million on a pre-tax basis of occupancy expense in the fourth quarter of 2024. On an after-tax basis, this will reduce fourth quarter diluted earnings per share by approximately $0.43.
As for the impact of ASC 842 in future years, it is expected that the correct calculation of lease expense will increase occupancy expense by approximately $1.6 million per year on a pre-tax basis.
It has evaluated the impact to income for each of the periods involved as well as the cumulative impact to 2024's results and have determined the understatement in the prior years as well as the impact to the results for 2024 are not material to the Bank's results of operations or its balance sheet.

PFBC

Preferred Bank Finds Unreconciled Difference In Its Calculation Of Its Right Of Use Asset And Lease Liabilities; Expects Additional Q4 Expense To Reduce Q4 EPS By $0.43

ASAI

Sendas Distribuidora Intends To Proceed With Voluntary Delisting Of Its ADSs From NYSE

BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.01) by 300 percent. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $143.00 million which missed the analyst consensus estimate of $150.76 million by 5.15 percent. This is a 18.29 percent decrease over sales of $175.00 million the same period last year.

BlackBerry Q3 2025 Sales $143.00M Miss $150.76M Estimate

FCPT

Four Corners Property Trust Reports Acquisition Of A MercyOne Outpatient Clinic Property For $2.8M

BlackBerry is providing the following guidance for the fourth quarter and the full fiscal year 2025 (ending February 28, 2025).&nbsp;
As the sale of the Company's Cylance business is expected to close during the fourth quarter of 2024, that business is reported this quarter as discontinued operations, and the following guidance, except for non-GAAP basic EPS, is reflective solely of the expected results of the Company's continuing operations.

BlackBerry Now Expects FY25 Total Revenue Of $517M - $526M (Est $603.12M), Non-GAAP Basic EPS Of $(0.02) - Breakeven (Est $(0.02))

BlackBerry Expects Q4 Total Revenue Of $126M - $135M (Est $161.49M), Non-GAAP Basic EPS Of $(0.01) - $0.01 (Est $0.01)

Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) has outperformed the market over the past 10 years by 5.27% on an annualized basis producing an average annual return of 16.19%. Currently, Arch Capital Group has a market capitalization of $33.48 billion. 
Buying $100 In ACGL: If an investor had bought $100 of ACGL stock 10 years ago, it would be worth $446.81 today based on a price of $88.99 for ACGL at the time of writing.
<h3>Arch Capital Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734646508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACGL

Here's How Much $100 Invested In Arch Capital Group 10 Years Ago Would Be Worth Today

Vivani Medical GAAP EPS of -$0.10 beats by $0.02

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vivani Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/vani-stock-quote/">VANI</a>) just reported results for the second quarter of 2024.<ul><li>Vivani Medical reported earnings per share of -10 cents. This was above the analyst estimate for EPS of -12 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vani-stock-earnings-vivani-medical-for-q2-of-2024/">VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024

Naz Rahman, an analyst from Maxim Group, has initiated a new Buy rating on Vivani Medical (VANI). Naz Rahman has given his Buy rating due to a comb...

Innovative Obesity Treatment Promises High Compliance: Buy Recommendation for Vivani Medical

Maxim Group analyst Naz Rahman reiterated a Buy rating on Vivani Medical (VANI – Research Report) yesterday and set a price target of $8.00. Naz Ra...

Buy Rating Affirmed for Vivani Medical on Strong Potential of NPM-115 Implant for Metabolic Disease Treatment

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Vivani Medical (VANI – Research Report) and keeping the price target at $8.00. Naz R...

Buy Rating on Vivani Medical: Advancing GLP-1 Therapies with Innovative Implantable Treatment

Catalyst Watch: Netflix earnings, Lenovo tech event, Paris Motor Show, and eyes on oil

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

JPMorgan, Five Below downgraded: Wall Street's top analyst calls

Vivani Medical GAAP EPS of -$0.11

Vivani Medical, Inc. ( ($VANI) ) has released its Q3 earnings. Here is a breakdown of the information Vivani Medical, Inc. presented to its investo...

Vivani Medical Reports Q3 Loss, Advances GLP-1 Trials

Vivani Medical Gains 'Buy' Rating Due to Strategic Advancements and Financial Strength

ADBE

ALGM

ALLY

AVDX

BLNK

BYDDF

CAPR

CROX

CTRI

CYTK

DLTR

FIVE

HUBS

IBTA

INTC

LNVGY

MIRM

MSFT

MTEN

NAPA

NFLX

NRBO

NVDA

NVNO

OCGN

OKTA

QCOM

SCHW

SERV

SFHG

SRPT

SRRK

TSLA

ULTA

USGO

VANI

VLKAF

VRSSF

ZYME

Press Releases

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

Penny Stocks

Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

AEMD

ASPI

ATWT

BIXT

BNRG

BTVRF

BVAXF

CMCL

CSE:BIOV

CSE:ELEM

CSE:PLUG

CSE:PMC

CYIO

ELMGF

EUDA

GDTC

GIFT

GOEV

GOSS

GOVX

ICON

IMRN

JETR

LDTC

MNMRF

MTWO

NCSM

NRXBF

NVAAF

PCYO

PENMF

PGEZF

PLGGF

PMCCF

RECAF

RGBP

SEVCF

SIGY

SKYH

STXPF

SUGRF

TSX:VGZ

TSX:VOXR

TSXV:BTV

TSXV:MNRG

TSXV:NRX

TSXV:PGE

TSXV:RECO

TSXV:STU

TSXV:SUG

TSXV:XBOT

UMAC

USEG

VIOT

VOXR

XBOTF

Apyx Medical

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

HeartBeam

CytoSorbents

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Vivani Medical

ニュース

最新ニュース Vivani Medical (NASDAQ:VANI) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル